Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia

Trial Profile

Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 May 2017

At a glance

  • Drugs Rosuvastatin (Primary) ; Eicosapentaenoic acid; Fenofibrate
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2012 Planned End Date changed to 1 Sep 2010 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top